Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Robust and proprietary enabling
DUB platform

Yielding novel therapeutics for the
benefit of patients

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need.

We have built a World-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

About Mission
Mission Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and other diseases of unmet need.

Mission Therapeutics’ DUB platform has enabled the development of a pipeline of DUB programmes that have been selected for their potential to address unmet needs in major disease areas with high commercial potential.

News & events
Keep up to date with our latest news announcements, and meet the Mission Therapeutics team at the following events.